Introduction
Disenchantment with the long-term side effects and response fluctuations of medical therapy has led to a re-evaluation of the role of surgery in the management of Parkinson's disease (Goetz and Diederich, 1996; Olanow 1996; Obeso et al., 1997 (Laitinen et al., 1992) coincided with the development of a deeper understanding of the neural mechanisms underlying Parkinson's disease symptoms, largely from experimental studies on the MPTP-exposed parkinsonian primate (Bergman, 1990; Aziz et al., 1991) . Briefly stated, this model suggests that loss of nigrostriatal dopamine leads to excessive putaminal inhibition of the lateral pallidum; this releases the subthalamic nucleus from inhibitory regulation, and this in turn excessively drives the posteroventral pallidum to inhibit the motor thalamus.
However, many questions remain unanswered regarding the role of pallidotomy in the treatment of Parkinson's disease. Despite reports from a number of different centres on the procedure's clinical efficacy (Dogali et al., 1995; Iacono et al., 1995b; Laitinen, 1995; Lozano et al., 1995; Baron et al., 1996) and the neurophysiological mechanisms putatively involved (Dogali et al., 1994; Grafton et al., 1995; Iacono et al., 1995a; Eidelberg et al., 1996; Obeso et al., 1997) , scepticism about the net clinical benefit of pallidotomy remains. There may be several reasons for this, including unacceptably high (i.e. 40%) complication rates reported at some centres (Sutton et al., 1995) , a lack of consensus regarding the optimal lesion size/site and/or surgical technique [i.e. microelectro-guided versus macrostimulation; staged versus simultaneous bilateral posteroventral pallidotomy (BPVP)] (Bakay et al., 1992; Friedman et al., 1996) or perhaps an intuitive difficulty accepting that selectively lesioning the brain can be beneficial in a progressive neurodegenerative disease. However, a lack of confidence in the timing, scope and objectivity of reported measures of clinical outcome and their ability to identify any occult deficits may also be an important factor.
The potential complexity of evaluating net benefit following pallidotomy is daunting in a progressive, multisystem disease with considerable variability both within and between individuals (Kelly, 1995) . Potential costs to the patient include known surgical complications. Iacono et al. (1995b) have reported visual field defects, hemiparesis, intracranial abscess and subcortical and intrapallidal haemorrhage, with an overall complication rate of 6.3% (later resolving to 3.2%); in addition, postoperative dysarthria, facial weakness, confusion (Baron et al., 1996) , sexual disinhibition (Dogali et al., 1995) and depression (Sutton et al., 1995) have all been observed. There have also been reports in the early literature of language deficits, albeit illdefined. For example, Leksell's group (Svennilson et al., 1960) observed word-finding difficulties and paraphasias in 24% of patients with lesions in the dominant hemisphere. Other studies noted spoken language deficits (Cooper and Bravo, 1958; Gillingham et al., 1960; Allan et al., 1966) ; however, the outcome from thalamotomy and pallidotomy was not differentiated in these series. The posteroventral pallidum is not known to be implicated in cognition or mood, but until the recent pilot study of outcome following unilateral posteroventral pallidotomy (UPVP) by Baron et al. (1996) there had been no reported attempts to systematically screen these domains. This is a significant oversight with an ablative procedure that demands precise targeting and perhaps optimal lesion volume and contour. There have been no reports of cognitive or psychiatric outcome following simultaneous BPVP.
With some exceptions (Laitinen et al., 1992; Laitinen, 1994; Baron et al., 1996) , most published operative series have based their evaluation of clinical outcome on Parkinson's disease symptom rating scales or protocols; the Core Assessment Program for Intracerebral Transplantation (CAPIT), the Unified Parkinson's Disease Rating Scale (UPDRS), the Hoehn and Yahr Scale (H&Y) and the Schwab and England Activities of Daily Living Scale (S&E) have been typically employed in large series (Dogali et al., 1995; Iacono et al., 1995b; Lozano et al., 1995; Baron et al., 1996) . Careful and independent neurological examination coupled with these more objective, structured observational methods is necessary, but arguably insufficient. The UPDRS, H&Y and S&E are inadequate for reliably accommodating varied and fluctuating symptomatology (i.e. the percentage of time/ disability in 'on' and 'off' states). Further, changes in one or more aspects of motor function (or the distribution of varied symptoms' frequency and intensity) are not necessarily accompanied by equivalent changes in the patients' functional disability or quality of life. A statistical improvement in dyskinesia or best 'on' score, does not necessarily imply a useful, worthwhile or cost-effective clinical outcome.
It is therefore important to include psychometrically sound self-report measures that take a more 'global' and patientcentred perspective on quality of life or functional disability when evaluating clinical outcome. There are also difficulties here; in such a disabled patient group, mood, expectations, motivation (e.g. to seek treatment), insight and medication regime may all influence responses. For example, a lack of insight into the severity of dyskinesias prior to surgery will lead to a flawed assessment of any postoperative improvement. Similar problems arise with neuropsychological assessment designed to screen for occult cognitive deficits. In particular, Parkinson's disease medications are known to influence mood, arousal and cognition (Gotham et al., 1988; Saint-Cyr et al., 1993) ; achieving ideal equivalence between baseline and outcome assessments in these terms can be problematic as one of the potential benefits of posteroventral pallidotomy is optimal adjustment in medication. Evaluating the net benefit of posteroventral pallidotomy (PVP) therefore requires careful consideration of the psychological context and clinical presentation of patients at all assessments.
In this paper we report cognitive, psychological and functional outcomes in a consecutive series of 20 parkinsonian patients who underwent UPVP or simultaneous BPVP; targeting was achieved using Image Fusion TM and Stereoplan TM (Radionics Inc., Boston, Mass., USA) with stimulation for lesion localization.
Method

Patient series
Patients with Parkinson's disease (Table 1) were selected from those referred to the movement disorder clinic staffed Medication: D ϭ L-dopa; Br ϭ bromocriptine; P ϭ pergolide; Ap ϭ apomorphine; Bz ϭ benzhexol; S ϭ selegeline; Dz ϭ diazepam; Am ϭ amantadine; L ϭ lysuride. DSM-IV diagnoses: PH ϭ previous history. HADS 'caseness': A ϭ anxiety caseness; D ϭ depression caseness. Cognitive profile: nviq ϭ non-verbal IQ; viq ϭ verbal IQ; att-def ϭ attentional deficit; mem-def ϭ memory deficit; s&l-def ϭ speech and language deficit.
by a neurologist and a neurosurgeon. All but two presented with rigid akinesia when in the 'off' state and/or severe druginduced dyskinesias when in the 'on' state. The Parkinson's disease symptoms of Patient 5 were well controlled apart from moderate grade 2 dyskinesias, which she felt were unacceptable because of her occupation. Patient 18, although known to be L-dopa-responsive, had refused to take any dopaminergic medication because of side effects that could not be controlled. All patients satisfied United Kingdom Parkinson's Disease Society brain bank diagnostic criteria for idiopathic Parkinson's disease (Gibb and Lees, 1988) and all had failed optimal medical therapy. A UPVP was performed on patients with asymmetrical dyskinesias and a bilateral procedure when symptoms and signs were not predominant on one side. Where possible, medication was unchanged for 3 months preoperatively and 3 months postoperatively. Three patients were excluded from the original consecutive series of 23. One died 2 months postoperatively of a gastrointestinal haemorrhage and two were not fluent in English and were therefore unable to complete neuropsychological assessment protocols. The 20 remaining patients included five with right and seven with left UPVP, and eight who had simultaneous BPVP.
Surgical technique
The surgical approach relied on anatomical localization with stimulation to confirm the accuracy of the targeting. Preoperatively patients had a T 1 -weighted MRI scan using a 3D Turbo-FLASH sequence (TE 7 ms, TR 15 ms) and a Siemens 1.5 T Magnetom Vision Scanner. This provided grey-white matter tissue contrast and excellent neuroanatomical definition. Then under general anaesthesia the Cosman-Robert-Wells frame was fixed to the patient and a stereotaxic CT scan acquired (using 2 mm contiguous slices parallel to the orbitomeatal line). Whilst the patient was transferred to theatre and prepared for surgery, the MRI scan was fused and spatially corrected to the CT scan using Image Fusion TM and Stereoplan TM to define the coordinates for the posteroventral pallidum, which could be clearly seen in the final image. A burr hole was made, the dura excised and the pia diathermized. The burr hole was sited just anterior to the coronal suture, 5.0 cm lateral to the midline. This offered an oblique approach that avoided the internal capsule and allowed a series of lesions to be made from medial to lateral with a single pass of the electrode. (In the first four patients in this series a more vertical approach was used with the burr hole 2.5 cm lateral to the midline. Postoperative imaging, however, showed that the electrode track transgressed the internal capsule.)
Having transferred the coordinates generated from the fused image to the Cosman-Robert-Wells frame, the electrode (2 mm exposed tip, 1.8 mm diameter) was passed to the target. The impedance of the medial pallidum, typically 500-700 Ω, was measured as the electrode was advanced into the ansa lenticularis, where it increased to 900-1100 Ω. The effect of stimulation at 20-100 Hz was studied and the threshold for exacerbation or alleviation of rigidity, bradykinesia and tremor determined. The target threshold was generally 1.0 V. Stimulation at 2 Hz up to 3.0 V was used to look for capsular responses or when in the ansa to look for visual phosphenes in order to ensure there was no encroachment on the internal capsule or optic tract.
Having located the target and confirmed it physiologically, a temporary lesion at 45°C for 1 min was made and the patient assessed for any untoward side effects. If none were present, a series of three lesions was made at 75°C for 30 s in the ansa, then two further lesions at 75°C for 60 and 90 s in 2 mm steps. This resulted in a 7 ϫ 4 mm lesion from the ansa through the posteroventral pallidum.
Timing of assessments
Patients completed a multidisciplinary assessment protocol in the 4 weeks preceding surgery and 3-4 months postoperatively. The latter time frame was considered long enough to ensure a significant degree of postoperative recovery (and the re-engagement of patients in normal everyday routines), but short enough to minimize the likelihood of any interference effects from disease progression.
Neurological assessment
Baseline and follow-up neurological assessments were completed independently of the surgeon. These comprised the UPDRS, in which the Total score is defined as the sum of parts 1-4 in the 'practically defined off state' (no medications overnight for at least 12 h, and 1 h after waking). 'Best on' (i.e. optimally medicated) and 'worst off' scores were also determined for part 2 (activities of daily living) and part 3 (motor examination), as described in the UPDRS protocol (Fahn and Elton, 1987) . H&Y and modified S&E scoring were also used. Tremor and dyskinesia scores were derived from the UPDRS. Dyskinesia scoring uses the arithmetic mean of patient-scored dyskinesia duration and examiner-scored severity (i.e. contralateral scores for UPVP and summed bilateral scores for BPVP). Duration of 'ontime' per day was derived from patient diaries. Confrontational visual fields were also plotted using a Humphrey field analyser.
Neuropsychological assessment
All language and cognitive assessments were conducted in the 'on' state. Given the length of the protocol, patients sometimes went 'off' during the assessment, which was then suspended till medication returned them to the 'on' state. Assessment comprised a semistructured clinical interview and the administration of psychometric tests and questionnaire measures. The interview included routine screening for any disturbances in mood, appetite, libido, sleep, sensoryperceptual function, intellect and thought (i.e. medicationinduced hallucinations or suicidal ideation). Patients were also questioned about their expectations regarding surgery, psychosocial circumstances, likely level of postoperative social support and any psychiatric history. The patient's carers, relatives or spouses were also interviewed. Where appropriate, Axis I diagnoses according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association, 1994) were confirmed.
Given the neuroanatomical and neurochemical complexity of basal ganglia-thalamocortical circuits (Alexander et al., 1986) , and with insufficient published data on cognitive outcome following PVP, the main aim of the neuropsychological test battery was that it should screen major domains of cognitive function. These domains need not necessarily coincide with the multiple selective cognitive deficits that have been reported in patients with Parkinson's disease (Raskin et al., 1990) , deficits that may be distinct from a more global dementia (Stern et al., 1993) . For example, memory and visuospatial impairments have been variously implicated in Parkinson's disease; however, it has also been suggested that a dysexecutive syndrome underpins many of the reported impairments (Brown and Marsden, 1990) . Given early reports of post-PVP language deficits (Svennilson et al., 1960) , a comprehensive speech and language screen was incorporated in the battery along with various tests of attention, memory, visuospatial ability and executive function. The choice of tests was, however, constrained by the severity of the patients' baseline dyskinesias (i.e. precluding the reliable administration of tests involving motoric function) and the exigencies of available clinical time. The likelihood of performanceenhancing practice/familiarity effects between assessments also strongly recommended the use of psychometrically sound parallel forms where available.
The Speech and Language screen was tape-recorded and included tests of vocabulary (Wechsler, 1981) , abstract verbal reasoning [i.e. 'similarities' subtest (Wechsler, 1981) ], categorical and phonemic verbal fluency (Spreen and Benton, 1991) , lexical decision making, speed of reading comprehension (Baddeley et al., 1992) , aural comprehension [shortened token test (Spreen and Benton, 1991) ], confrontation naming (McKenna, 1983) and repetition (Goodglass and Kaplan, 1972) . Speech articulation rates were also assessed as a rapid and simple screening device (Portnoy and Aronson, 1982; Kent et al., 1987) for changes in speech motor apparatus (i.e. number of correct pronunciations of 'mama', 'papa', 'thanks', 'pitter-patter', 'pa-ta-ka' and 'caterpillar' in 5 s). Overall verbal ability was estimated by pro-rating a quotient according to Tellegen and Briggs (1967) based on vocabulary, similarities and digit span subtest scores. Non-verbal reasoning and visuospatial ability were assessed with Ravens Standard Progressive Matrices; raw scores were converted into non-verbal IQ estimates (Peck, 1970) . Various attentional parameters were also assessed; auditory-verbal 'working' memory with forward and backward digit span (Wechsler, 1981) , visual selective attention/speed with the Stroop Test (Trenerry, 1989) , attentional switching with the Visual Elevator Test (Robertson et al., 1996) and a sequential operations series. In this last test patients were required to recite the alphabet, prefacing each letter with a consecutive number (i.e. 1-A, 2-B µ 26-Z); three timed trials were permitted and the score was calculated by dividing the elapsed time by the correct number of number-letter strings. Memory was assessed by testing the immediate and delayed recall of a short story, word list learning (Coughlan and Hollows, 1985) and recognition memory for words and faces (Warrington, 1984) . Unless otherwise stated, all tests were administered and scored in the manner specified in the relevant test manuals.
Questionnaire measures comprised the Functional Limitations Profile (FLP), the Medical Outcomes Study Short Form (SF-36), the Hospital Anxiety and Depression Scale (HADS) and the Parkinson's Disease Questionnaire (PDQ-39). The FLP (Patrick and Peach, 1989 ) is the UK version of the Sickness Impact Profile (Bergner et al., 1981) , a multidimensional, reliable and well-validated measure of functional disability that has been used with a variety of medical conditions including Parkinson's disease (de Bruin et al., 1992; Wilkin et al., 1992) and recently endorsed by the Medical Outcomes Trust in the USA. The SF-36, a generic measure of quality of life, also has excellent psychometric properties, and normative data from a wide variety of patient groups including Parkinson's disease (Jenkinson et al., 1993) are available. The PDQ-39 (Peto et al., 1995) is a diseasespecific quality of life measure that (together with the SF-36) has been shown to be sensitive to the effect of Parkinson's disease (Jenkinson et al., 1995) . The HADS is a measure of anxiety and depression designed to screen out somatic symptoms where a score greater than 8-10 indicates a level of 'caseness'.
Statistical analysis
Patients acted as their own controls. The KolmogorovSmirnov test was first used to confirm that mean differences between baseline and follow-up scores on all psychometric measures were normally distributed. Thereafter, a paired sample t test was employed to test the null hypothesis of no difference between baseline and 3-month follow-up scores on questionnaire measures and psychometric tests. Having performed over 60 t tests in these analyses, a more conservative alpha value of 0.01 was chosen to reduce the chances of making a type I error. The UPDRS, H&Y and S&W yield ordinal data, so the Wilcoxon signed rank test (two-tailed) was employed to test for significant (alpha Ͻ 0.05) postoperative changes on these scales. Table 1 outlines selective features of patients' clinical presentation preoperatively; Table 2 presents preoperative, individual UPDRS and H&Y scores. The group comprised 11 women and nine men with a mean age of 57.9 years and mean time since (Parkinson's disease) diagnosis of 11.8 years. Five had a previous psychiatric history, and two satisfied the criteria for current diagnoses on Axis I of DSM-IV; 11 scored above a level of 'caseness' (8-10) on the anxiety and/or depression scales of the HADS. Mean estimated verbal (102.6) and non-verbal (106.5) IQ for the series fell in the average range; however, all but four patients presented with various attentional, memory or speech and language deficits (defined as a standard score on any test sensitive to one of these domains that fell by Ͼ1 SD below the control mean). The mean reported level of functional disability on the FLP (i.e. total score) was 23.8%; this compares with reported scores of 3% in a general population sample (Gilson, 1979) to 44% in a frail elderly sample (Mulrow et al., 1994) . Table  3 presents preoperative scores on the SF-36 for our series together with the means of scores obtained from Parkinson's disease patients (n ϭ 137; mean age 66.9 years; mean time since diagnosis 6.73 years) seen in a general neurological clinic (Jenkinson et al., 1995) . Although there was considerable individual variability in scores reported in our series, the group mean scores on all SF-36 dimensions (except role limitations mental, mental health, energy and vitality, and health perceptions) fell below and outside the 95% confidence intervals of those reported from the clinic sample.
Results
Preoperative patient characteristics
Group outcome Neurological outcome, UPDRS, H&Y and S&E
The mean total UPDRS score was 82 Ϯ 23 preoperatively and 51 Ϯ 25 postoperatively, an improvement of 38% (P Ͻ 0.001). BPVP produced an improvement of 53% (from 88 Ϯ 22 to 41 Ϯ 21) and UPVP produced an improvement of 27% (from 78 Ϯ 23 to 57 Ϯ 22), consistent with the added benefit of operating on both sides. For all patients, significant improvements were observed in UPDRS contralateral dyskinesia scores, with a mean of 2 Ϯ 1.5 improving to 0.5 Ϯ 1.0 (P Ͻ 0.001). Contralateral tremor also improved significantly (P Ͻ 0.05), although this was not as predictable as the effect on dyskinesias. The UPDRS activities of daily living score improved mostly in the 'off' state (from 22 Ϯ 7 to 15 Ϯ 9) compared with the 'on' state (13 Ϯ 7 to 10 Ϯ 6), although both changes were significant (P Ͻ 0.01 and P Ͻ 0.05, respectively). UPDRS motor examination scores also changed significantly, with similar changes in both the 'off' (from 48 Ϯ 17 to 27 Ϯ 14; P Ͻ 0.001) and 'on' states (from 24 Ϯ 17 to 16 Ϯ 11; P Ͻ 0.001). Percentage 'off' times decreased from a mean of 35 Ϯ 22% to 21 Ϯ 19% postoperatively (P Ͻ 0.05). Modified S&E improved from a mean of 60 to 78 (P Ͻ 0.001), as did H&Y 'on' and 'off' scores (P Ͻ 0.01 and P Ͻ 0.05, respectively). According to the study protocol, no regular prescribed medications were changed for 3 months postoperatively. However, three patients could not be prevented from reducing or stopping their apomorphine injections, which were being taken on an asrequired basis; these changes were due to a postoperative reduction in 'off time'. In order to ensure that these reductions did not have a significant effect on the overall group outcome, postoperative UPDRS changes were analysed for the remaining 17 patients; we found no change in the significant improvements detailed above. After the 3-month postoperative assessment, dopaminergic medications were reduced in 11 patients, in whom the duration and intensity of the 'off' state had attenuated, and were increased in two patients, in whom attenuated/abolished dyskinesias enabled further optimization of medication.
Functional disability and quality of life Table 4 presents the mean baseline and postoperative scores for all questionnaire measures. All subscale scores changed towards improved quality of life (SF-36 and PDQ-39), reduced functional disability (FLP) or reduced anxiety/ depression (HADS). The lack of significant change in a number of subscales may be due to insufficient statistical power: the PDQ-39 was completed by only 13 of the sample, and was therefore most vulnerable in these terms. Significant improvement was observed only on the PDQ-39's activities of daily living (P Ͻ 0.01), mobility (P Ͻ 0.01) and bodily discomfort (P Ͻ 0.01) subscales, although improvements in emotional well-being (P Ͻ 0.05) and stigma (P Ͻ 0.05) were approaching statistical significance. Despite more general concerns about the sensitivity of the SF-36 to change (Jenkinson, 1993) , significantly improved 'quality of life' in terms of physical and social functioning (P Ͻ 0.01), bodily pain (P Ͻ 0.001) and energy-vitality (P Ͻ 0.001) was observed postoperatively. Patients 'in general' (i.e. subscale 8) viewed their overall health in much the same terms pre-and postoperatively; however, their perception of improvements in health (P Ͻ 0.001) 'compared with one year ago' (i.e. subscale 9) changed significantly. This apparent contradiction may reflect the patients' distinction between selective symptomatic improvement, with no change in underlying progressive disease. Insufficient power is likely to explain why change on at least two subscales (i.e. 3 and 4) did not achieve statistical significance, as they comprise only three and four items, respectively.
Significant reductions in functional disability were observed in four individual categories [ Table 4 : category 9 (P Ͻ 0.01), categories 2, 5 and 6 (P Ͻ 0.001)] of the FLP, and improvements in all other domains except eating, emotion, work and communication were approaching statistical significance (P Ͻ 0.05). Overall dimension scores of the FLP are, however, known to be the most robust and reliable scales (Charlton et al., 1983) , and when individual category scores were combined into the 'physical', 'psychosocial' and 'total' dimensions (Table 3) , significant postoperative reductions in functional disability were found (P Ͻ 0.001). With regard to psychological symptomatology, the mean HADS anxiety score was at a level of 'caseness' preoperatively and fell significantly (P Ͻ 0.01) below 'caseness' postoperatively; an improvement in depression score was approaching statistical significance. Table 5 presents the mean baseline and postoperative scores for selected psychometric tests. With the exception of the story memory, list learning, visual elevator, lexical decision making and speed of reading comprehension tasks (where alternative forms and normative data were available), other tests administered were more or less susceptible to practice/ familiarity effects, given the relatively short test/retest interval. Although it has been suggested (Beatty and Scott, 1993 ) that practice effects are less marked on tests of vocabulary, abstract verbal reasoning, confrontation naming, verbal fluency, the Stroop test, the token test and speeded tests of overlearned material (all of which are tasks employed in this study), it is important to note that any such unquantified effects would increase the chance of making a type II error. We observed no significant group changes in Ͼ25 psychometric test variables (Table 5) other than a reduction in categorical verbal fluency scores; 'animals' fluency fell by 14% (P Ͻ 0.01), 'things to eat' fluency by 20% (P Ͻ 0.001) and a combined categorical fluency score by 17% (P Ͻ 0.001). With no changes in diadochokinetic rates, sequential operation series scores or the colour score of the Stroop test (i.e. simple reading rate), this deterioration in verbal fluency is unlikely to be related to any slowing in speech-motor apparatus or problems with initiation. Further, there were no significant changes in confrontation naming errors or response latency, comprehension, vocabulary, abstract verbal reasoning or repetition that might suggest a more general language impairment. Table 7 . No deaths occurred as a result of surgery and no patient sustained a haemorrhage. MRI scanning 48 h postoperatively confirmed satisfactory lesion placement. There was only one intraoperative complication (Case 2), where the surgical lesion encroached on the internal capsule; however, the resulting hemiparesis, hemianopsia and dysarthria were mild and subsequently resolved. In two other cases the surgical lesion was too conservative; Case 1 derived some immediate clinical benefit (at the 3-month assessment), but her dyskinesias had returned by the 6 months follow-up; Case 4 derived only marginal clinical benefit; both patients elected to undergo the procedure again. Other postoperative changes that were reported included worsening dysarthria and/or dysphonia, hypersalivation/drooling and weight gain. Twelve cases reported an average weight gain of~11.5 lb, a change explained by the patients in terms of both improved appetite and functional dexterity. Despite there being minimal changes in group cognitive outcome, there was considerable individual variation. Table  6 illustrates this variation in simplified terms by highlighting the patients' cognitive gains and deficits (i.e. change in a relevant test score of more than one standard deviation from baseline to 3-month assessment). One patient in particular (Case 17), who had a BPVP, complained of fatigue, low levels of arousal and intermittent confusion at the 3-month follow-up; her performance on a range of psychometric tests was also found to have deteriorated significantly, although her UPDRS total score had reduced by 50%. In contrast, four patients' estimated verbal or non-verbal quotients increased postoperatively by Ͼ15 scaled score points.
Cognition
Individual outcomes
There were no new individual instances of HADS 'caseness', but one case of a worsening psychiatric condition and one new DSM-IV diagnosis. At baseline assessment, Case 10 satisfied the criteria for a diagnosis on Axis I of DSM-IV of generalized anxiety disorder (300.02); she also had a previous history of major depressive disorder. There was an excellent neurological result, but postoperatively she developed a psychotic depression (296.24) which is likely to have been precipitated by an inadvertent and substantial increase in a dopamine agonist; her depression did not respond to medication and required electroconvulsive therapy, which gave excellent results. Although her clinical presentation was psychiatrically unremarkable at the 3-month follow-up, her scores on the anxiety and depression subscales of the HADS remained above a level of 'caseness' and her cognitive performance was found to have deteriorated on a number of psychometric tests.
Case 6 had a history of eating disorder (307.50) and at baseline assessment satisfied the criteria for diagnoses of panic disorder without agoraphobia (300.01) and generalized anxiety disorder (300.02) on Axis I of DSM-IV. Her anxiety was particularly associated with anticipating 'off' states. In the first few weeks postoperatively she was able to stop her apomorphine infusion, but felt unable to employ her customary 'signal' (i.e. a sense of increasing rigidity in both legs) of impending 'off' periods as effectively as before the operation. Having had a right posteroventral pallidotomy and marked reduction in contralateral rigidity, her feeling of rigidity in the ipsilateral leg was subjectively exaggerated by comparison. The experience of psychosensory disequilibrium was significant in her case as it caused exacerbation of anticipatory anxiety; the frequency and intensity of her panic attacks therefore increased in the transitional period between 'on' and 'off' states. With careful in-patient monitoring of her medication regime and the provision of appropriate anxiety management strategies, her psychological symptoms gradually attenuated.
Subgroup outcomes
Differences between baseline and 3-month follow-up scores were also analysed for the following patient subgroups: right (n ϭ 5) and left (n ϭ 7) UPVP, all UPVPs (n ϭ 12) and BPVP (n ϭ 8). Although the findings from such small subgroups can only be interpreted with caution, over and above those changes reported above for the group as a whole no clinically or statistically meaningful differences were found in the cognitive or functional outcome of patients who had left as opposed to right UPVP. There was, for example, no identifiable trend towards more marked speech, language or verbal fluency deficits following either left or right UPVP.
With regard to quality of life and functional disability, the trend towards significant improvement on subscales identified for the whole series was maintained. Table 8 , for example, illustrates comparable percentage reductions in functional disability (i.e. FLP) following UPVP and BPVP. A significant postoperative change in combined speech articulation rates (P Ͻ 0.01) was, however, apparent when outcomes for the eight BPVPs were examined separately. On further questioning, only four of these patients (and/or their relatives/carers) subjectively confirmed slight worsening of pre-existing problems with speech articulation, hypophonation and/or hypersalivation/drooling (there was no reported dysphagia, although changes in swallowing may underpin the latter reports); only Case 2 spontaneously reported dysarthria with noticeable functional consequences. Patients with BPVP also demonstrated a significant 21% fall in phonemic verbal fluency scores (P Ͻ 0.01) and a 13% fall in combined categorical fluency scores (P Ͻ 0.01) not reported subjectively. In contrast, for the 12 patients with UPVP the combined categorical fluency rate fell significantly by 20% (P Ͻ 0.001), but there was only a 2% reduction in phonemic fluency.
The first four cases of the series are also of interest as the surgical approach (2.5 rather than 5.0 cm lateral to the midline) and the resulting lesion location, contour and volume were different. For the reasons stated above, from the fifth case onwards the patients had serial lesions along the same trajectory made every 2.0 mm from the ansa lenticularis with an electrode having a 2.00 mm exposed tip and 1.8 mm diameter. The lesions on MRI were cone-shaped with the long axis at 50-60°to the vertical. The initial four cases had vertical lesions made with an electrode having a 5.0 mm exposed tip and 2.0 mm diameter, such that lesions were large and extended vertically. Interestingly, those that had clinically effective lesions (Cases 1-3) at the 3-month followup were the only patients in the series whose memory scores at this time (i.e. the delayed recall of verbal material) had deteriorated by Ͼ1 SD relative to baseline; these changes were statistically significant (P Ͻ 0.001). There were, however, no significant changes in any other psychometric test scores for this subgroup.
Differences between baseline and 3-month follow-up scores on psychometric tests and questionnaire measures were also analysed for all patients except those who had changed their apomorphine intake before the follow-up assessment. For this group (n ϭ 17), there was a reduction in the alpha value (from Ͻ0.01 to Ͻ0.05) on the physical functioning subscale of the SF-36, and changes in the anxiety subscale of the HADS no longer achieved significance; however, a significant improvement (Ͻ0.01) in the alertness category of the FLP emerged. Other than these changes, all other improvements in quality of life and functional disability for the group as a whole detailed above remained significant. There was no significant change in the neuropsychological outcome.
Discussion
In this consecutive series we found that PVP is effective in alleviating drug-induced dyskinesias, rigidity and 'on-off' phenomena in patients with Parkinson's disease; contralateral tremor was less reliably reduced and we observed no beneficial effects on freezing. The observed postoperative improvements in UPDRS, H&Y and S&E scores confirm the findings from other operative series (Dogali et al., 1995; Iacono et al., 1995b; Lozano et al., 1995; Baron et al., 1996) . In addition we are able to confirm that these symptomatic changes translate into significant improvements in patientrated quality of life and reductions in functional disability.
These gains must, however, be weighed against both predictable and unanticipated costs of PVP to the individual patient. With regard to intra-or postoperative complications, the risks remain unclear as classifications in the literature are often ill-defined. For example, many postoperative deficits are reported to be 'transient' (Dogali et al., 1995; Iacono et al., 1995b; Baron et al., 1996) , but adequate description of the gradient or extent of recovery is characteristically lacking and indeed may be impossible in a progressive neurodegenerative disease. Further, a clear distinction is generally not made between intraoperative complications (e.g. haemorrhage) that may or may not have long-term sequelae and postoperative complications (e.g. dysarthria) that may be associated with a well placed lesion and an otherwise good neurological outcome.
Accuracy is clearly paramount for the safety and efficacy of posteroventral pallidotomy. Localization techniques vary from one centre to another, and include microelectrode recording, CT-or MRI-guided stereotaxy and image fusion techniques with functional maps; we have adopted the latter technique for several reasons. Evidence from a number of experimental perspectives (Alexander and Crutcher, 1990) has defined the primate somatotopy of the pallidum. The target site can be clearly defined stereotactically by image fusion techniques and confirmed by stimulation. With available intraoperative neurological examination, microelectrode recording may therefore be unnecessary for localization; it increases the length of the operation and possibly the risk of intraoperative complications. For example, Baron et al. (1996) have reported two haemorrhages (with implied neuropsychological sequelae), one capsular lacuna (with transient dysarthric sequelae) and one quadrantanopsia, suggesting a complication rate of at least 26% in a pilot series of 15. Obeso et al. (1997) also describe 23 intraand postoperative complications in a larger series of 128 procedures (18.0%) from Emory University Medical School in Atlanta (Ga., USA), but argue that microelectrode mapping is not associated with an increased complication rate. Surgical technique may have other implications for net clinical outcome, in so far as the trajectory of the probe into the posteroventral pallidum can effect the location, contour and volume of the lesion. For example, we note the deficits in delayed verbal recall in the first four patients in our series, and that 'memory' deficits have been reported in primates following lesions in the pallidum (Gambaryan and Sarkisyan, 1983) .
This study has identified other potential 'costs' associated with PVP, which otherwise achieves an excellent neurological outcome. The intraoperative complication rate in this series was 5%. With regard to postoperative complications we have quite deliberately been exhaustive in screening patients for any changes, even if not necessarily associated with surgery or any reported or observed functional consequences (see Postoperative changes in Table 6 ). Excluding Case 2, all four reports of worsening in pre-existing dysarthria, hypophonia or hypersalivation/drooling were following BPVP; however, any changes were marginal and without functional consequences, and were elicited subjective impressions rather than spontaneous complaints. The weight gain reported in 12 cases was similarly not problematical; indeed, patients invariably felt they had been underweight preoperatively. Recent research (Toth et al., 1997) has suggested that weight loss in Parkinson's disease is due to reduced daily energy expenditure (despite elevated resting energy expenditure due to rigidity, tremor and dyskinesias). Other individual observations included increased falling in the 'off' state in one patient (Case 20) ; this may reflect a relative failure to lesion the leg area compared with the upper body, thereby causing a disproportionate effect on bradykinesia improvement. Having carefully considered the severity of sequelae in terms of the quality of reports, patients' overall clinical presentation and the presence of any measurable functional consequences, we concluded that only Cases 2 and 16 experienced clinically significant postoperative complications (10%).
Excluding Case 2, all problems with the speech-motor apparatus occurred following BPVP; four subjective reports were consistent with changes observed in a more objective measure of speech articulation rates. Although impaired diadochokinetic rates have been reported in Parkinson's disease patients (Tatsumi et al., 1979) , this measure is not without practical and interpretative difficulties (Kent et al., 1987) and we did not employ sophisticated acoustic or physiological instrumentation. Nevertheless, standardized assessments to comprehensively quantify and fractionate speech deficits do not exist, and the physiological correlates of perceptual-acoustic disturbances in Parkinson's disease have yet to be determined (Gentil and Pollak, 1995) . Speech involves co-ordination of the complex movements of a number of different subsystems (i.e. laryngeal, velopharyngeal, respiratory and orofacial), all of which may be impaired in Parkinson's disease. In the past, significant preoperative dysarthria (or dysphonia) has been considered a contraindication for PVP (Selby, 1968) and the risk of further deficit following bilateral lesions has also been noted (Critchley, 1981) . The available evidence therefore points to post-BPVP changes in the speech-motor apparatus, although we are unable to specify the quality or aetiology of these changes; the need for more detailed and specialized investigation of this domain is clearly indicated.
Analysis of cognitive outcome for the whole series indicated that there was no significant change in over 25 neuropsychological variables following PVP; similar findings have been reported (Baron et al., 1996) following UPVP. As all assessments were administered in the 'on' state, it is not known if PVP might affect cognitive function in the 'off' state. However, a postoperative deterioration in verbal fluency, not reported elsewhere, has been observed. UPVP (left or right) was associated with selective reductions in categorical fluency, and BPVP with reductions in phonemic fluency, categorical fluency and speech articulation rates (Table 9 ). In the absence of any evidence to suggest more general postoperative language impairment or problems with speech initiation following UPVP or BPVP and no change in speech articulation rates following UPVP, no immediate explanation for the selective distribution of these changes after PVP is apparent. Selective verbal fluency deficits have been described in Parkinson's disease (Gurd and Ward, 1989) , but the posteroventral pallidum is not known to be involved in these tasks, although language impairments have been associated with large lesions in other basal ganglion structures (Laplane et al., 1989; Bhatia and Marsden, 1994) . Left (n ϭ 7) 12% (increase) (n.s) 5 % (increase) (n.s) 20% (P Ͻ 0.01) Right (n ϭ 5) 9% (increase) (n.s) 12% (n.s) 17% (P Ͻ 0.01) Unilateral (n ϭ 12) 10% (increase) (n.s) 2% (n.s) 20% (P Ͻ 0.001) Bilateral (n ϭ 8) 15% (P Ͻ0.01) 21% (P Ͻ 0.01) 13% (P Ͻ 0.01) All PVPs (n ϭ 20) 2% (n.s) 9% (n.s) 17% (P Ͻ 0.001) PVP ϭ posteroventral pallidotomy.
PET, functional MRI and neuropsychological studies suggest that word retrieval is dependent on a distributed network of component cognitive processes, with categorical and phonemic fluency tasks activating both temporal lobemediated semantic and frontal lobe-mediated strategic search processes, but to different degrees (Frith et al., 1991; Boivin et al., 1992; Martin et al., 1994) . Functional MRI studies (Pujol et al., 1996) , for example, have demonstrated that the phonemic fluency task preferentially activates the left dorsolateral frontal cortex, and it has been postulated that this is because the strategic search for words on the basis of their phonetic characteristics requires the participation of 'articulatory devices'. Categorical fluency places greater demands on temporal lobe-mediated semantic knowledge, but projections from the dorsolateral frontal cortex to the superior temporal cortex have been described (Pandya and Barnes, 1987) , and task performance may also in part depend upon the involvement of intact striatofrontal projections in the bilateral deactivation (or inhibition) of superior temporal circuits (Frith et al., 1991; Gurd, 1995) .
Disruption to the striatofrontal projections described by Alexander and Crutcher (1990) may therefore be associated with the postoperative verbal fluency deficits we have observed, in particular the changes in phonemic fluency and articulation rates that follow BPVP. We did not, however, observe any other postoperative frontal or executive deficits in behaviour (e.g. disinhibition or abulia) or test performance (e.g. attentional switching tasks). A variety of executive cognitive and behavioural deficits (including phonemic fluency) have been described following subtotal bilateral lesions of the globus pallidus; however, damage was not characteristically confined to the posteroventral pallidum (Laplane et al., 1989; Haaxma et al., 1993) . There has also been at least one recent report (Owen et al., 1996) of a relationship between activation (i.e. regional cerebral blood flow) in the right posteroventral pallidum and cognitive function (i.e. performance in a non-verbal planning/problemsolving task normally associated with the dorsolateral frontal cortex) in patients with Parkinson's disease. Further research with additional tests of executive function may therefore be indicated.
Some patients (both individuals and subgroups) demonstrated various postoperative deficits or gains in a variety of cognitive domains (Table 6 ). The standard error of measurement of the tests employed is unlikely to explain all of these changes, given their magnitude. Only Case 16 subjectively reported general intellectual difficulties subsequently confirmed by psychometric assessment. With satisfactory lesion placement, no intraoperative complications and a 50% improvement in total UPDRS score, these sequelae remain unexplained and are therefore of particular concern. Longer-term follow-up of this patient continues as her medications are adjusted. There were also at least three patients with BPVP (Cases 7, 17 and 20) and one with UPVP (Case 2) who reported and demonstrated a marked overall improvement in cognition postoperatively. Although Case 7 had reduced his apomorphine intake, changes in medication cannot account for improvements in the other two cases.
It may be that substantial improvements in motor disability and reductions in enforced inactivity had an unquantifiable secondary effect on attention and motivation. Alternatively, individual or subgroup changes in cognition may be associated with as yet unidentified variations in the contour, volume or location of the pallidal lesion.
Postoperative psychiatric morbidity was observed in two patients with UPVP, but in one case unintended changes in medication forestalls the conclusion that the lesion was directly responsible, and in the other it was neurological improvement that paradoxically precipitated the worsening of a pre-existing anxiety disorder. However, our experience with these (and other subsequent) patients suggests that comprehensive preoperative neuropsychological evaluation and postoperative management has an important role to play in multidisciplinary neurorehabilitation following PVP. In our view the ability of patients to adjust psychologically to a significant reduction in functional disability or a change in the pattern (or predictability) of 'on-off' phenomena should not necessarily be assumed.
The risk of intraoperative complications, postoperative changes in speech motor apparatus or cognition, and psychological maladjustment must therefore be weighed against demonstrable neurological gains following PVP to achieve a perspective on the net benefit. The 'quality of life' concept approximates net benefit in so far as it samples a patient-centred, global perspective on outcome. In these terms, our patient series strongly endorses the net benefit of PVP. The immediate postoperative response of the patients to the alleviation of symptoms was in some cases euphoric, but we did not form the impression that their questionnaire ratings at the 3-month follow-up merely reflected an extended postoperative 'honeymoon' period.
The improvements we observed in the physical functioning, social functioning and energy-vitality subscales of the SF-36 mirror other findings (Baron et al., 1996) ; however, we also found a significant reduction in pain. Pain is a common sensory disturbance in Parkinson's disease (Sandyk et al., 1988 ) but its precise aetiology remains uncertain; it can be bilateral or contralateral to motor symptoms (Snider et al., 1976) in many different parts of the body (Chudler and Dong, 1995) . Despite the subjective significance of pain reduction to patients, the SF-36 measure of pain is not sufficiently detailed to enable us to comment on whether postoperative reductions might be due to the alleviation of either primary (i.e. originating in PNS or CNS) or secondary (i.e. caused by oedema, dystonia, muscle cramps, etc) sensory symptoms (Snider and Sandyk, 1987) . Improvements in questionnaire measures of physical functioning might be predicted, given UPDRS findings; however, it is encouraging that we also observed significant gains in psychosocial functioning (i.e. FLP social interaction, recreation, sleep and rest; SF-36 social functioning). The possibility cannot be excluded that improvement in subscales like SF-36 energyvitality, HADS anxiety [or a general trend (i.e. P Ͻ 0.05) towards gains in SF-36 general mental health, FLP alertness, HADS depression and PDQ-39 emotional well-being and stigma] reflects the adjustment of some primary neurochemical imbalance. However, these beneficial changes in mood, alertness and vitality may also be a secondary psychological reaction to the alleviation of disabling Parkinson's disease symptoms. Patients' subjective reports of improved appetite, sleep and rest and weight gain and occasional reports of improved libido may also be secondary in this sense.
The analysis of post-PVP changes in terms of group means on a range of psychometric measures is a necessary research strategy; however, patients considering PVP might be forgiven for being more interested in individual variations in outcome. This variation must remain of interest and/or concern until more research has focused on mapping the functional architecture of the globus pallidus. Similarly, despite the fact that questionnaire constructs or dimensions are rated by patients themselves, the post-PVP outcome is not experienced by individuals in this modular fashion. In the final analysis there may be [as has been argued in relation to L-dopa (Sacks, 1982) ] a great deal of individual variation in cognitive, emotional and behavioural responses to PVP which, like the quality of life concept, defies actuarial analysis. Individual patients are in the best position to judge the impact of Parkinson's disease, and clearly the extent of pre-existing psychosocial or physical handicap will exert a powerful influence over their readiness to accept a degree of risk or symptom trade-off. In order to empower patients to take an appropriately balanced view, we would argue that it is the responsibility of a multidisciplinary movement disorder team to ensure that consent for PVP is informed by evidence on multidimensional aspects of outcome. As more is learnt about any unintended postoperative complications associated with a well placed lesion, the need for properly integrated multidisciplinary neurorehabilitation is also indicated.
Conclusions
We conclude that at the 3-month follow-up there is a net benefit associated with UPVP and BPVP for Parkinson's disease using Image Fusion © and Stereoplan © . These findings, however, need to be expanded and confirmed with larger numbers and longer follow-up; the latter is continuing in our patient series, over 70% now having reached the 12-month follow-up with no significant diminution of postoperative gains.
Our finding of net benefit is based upon a multidimensional assessment protocol that incorporates standardized observational, self-report and psychometric measures; in particular patients' perceptions of overall gains in quality of life and reductions in functional disability and psychological symptomatology were encouraging. However, our findings of marked individual variability in outcome, in particular with regard to cognition, must sound a cautionary note until further research can establish if these changes are associated with variations in the volume, contour or placement of pallidal lesions.
In our view, a randomized clinical trial comparing PVP with standard medical practice in this patient group would be ethically and practically unworkable. However, the closest possible approximation of this type of study is clearly a crucial next step in evaluating the efficacy of PVP; the Oxford Movement Disorder Group (together with other UK centres) is currently exploring alternative randomized methodologies.
